There have been no new therapies for genital herpes in 20 years. GEN-003 has consistently and safely improved several important genital herpes disease parameters in clinical studies.
Genocea understands that cancer is personal. We are leveraging our ATLAS platform to identify new targets that are specific to each individual. Our expertise in vaccinology enables us to turn those targets to personalized cancer vaccines.
Deep pipeline of medicines that matter.
Genocea is focused on the continued clinical development of GEN-003 and on advancing its personalized cancer vaccine program into the clinic. In addition, it has a number of clinical and pre-clinical infectious disease programs available for partnering.